Parallel in Medical Technology
Navigation Links
Parallel in Medical Technology
... IIIb study.
Sulkowski, M. et al. Late-Breaker parallel Session 16, Saturday, April 26,
4:45 p.m. Hall ... EPIC3 program. Poynard, T. et
al. Late-Breaker parallel Session 16, Saturday, April 26, 4:00 p.m. Hall ... with boceprevir (SCH503034). Susser, S.
et al. parallel Session 7, Friday April 25, 5:00 p.m., Hall 000.
...
... colleagues conducted a 24-week, double-blind, randomized, dose-ranging, parallel design trial of MTC monotherapy in 321 people with Alzheimer's at 17 ... in mild Alzheimer's disease: A randomized, controlled, double-blind, parallel Group, multi-centre, multi-country clinical trial." (Funder: Danone ...
... --- --- --- Trial Design TASKi3 was a 3 month, multi-center, randomized, double blind, placebo controlled, parallel dose clinical trial involving 219 RA patients in the U.S. who had failed to respond to at least one biologic treatment (such as TNF inhibitors). The ...
... no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. (1) "Randomized, parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation," ...
... PLX4032 works in a highly innovative way by selectively inhibiting the cancer-causing BRAF mutation, and is being developed in parallel with a companion diagnostic to identify mutation-positive patients. These data represent a significant development in the treatment of melanoma for ...
... in an extended release formulation for chronic pain. Study Design This Phase 3, double-blind, randomized, active- and placebo-controlled, parallel group, multi-center trial of 901 patients with moderate-to-severe pain following bunionectomy studied the safety and efficacy of tapentadol IR for ...
... metastatic and recurring forms of cancer. Under the alliance, GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will develop one of its own monoclonal antibodies through to clinical proof of concept, at which point GSK will have an exclusive option to ...
... for very high triglycerides and phase 2 protocols for statin combination therapy are currently being finalized with input from experts and the FDA in parallel with partnering discussions. About DCCR DCCR, diazoxide choline controlled release, is an ATP-dependent potassium channel agonist with ...
... results from the HORIZONS AMI trial showed ischemia-driven TLR was reduced by 41 percent with DES compared to BMS (4.5% vs. 7.5%, p=0.002), with parallel reduction in ischemia-driven target vessel revascularization (TVR) among patients treated with DES (5.8% vs. 8.7%, p=0.006). Angiographic follow-up ...
... Design The efficacy and safety of TRILIPIX in combination with rosuvastatin calcium was evaluated in a multicenter, randomized, double-blind, parallel group, 12-week, Phase III study of 760 patients with mixed dyslipidemia. Patients included in the study had multiple lipid problems, with an LDL ...
... President and CEO commented, "We are delighted to have completed patient enrolment in this phase 3 cardiac surgery trial, which we are running in parallel with the second phase 3 trial in colorectal surgery. Previous meetings with FDA have indicated that no other clinical trials are necessary for NDA ...
... Phase I clinical trials in the U.S. and continues to work closely with KLS in order to coordinate their regulatory efforts and efficiently conduct parallel clinical trials for TG-C in both the U.S. and Korea. The Phase IIa clinical trial is designed as a randomized, multi-center study in order to ...
... Amicus and its partner Shire HGT plan additional discussions with the EMEA in the first half of 2009 to finalize the design of this study. In parallel with the Phase 3 regulatory discussions, 23 of the original 26 patients from the Phase 2 studies continue to be treated in a voluntary extension ...
... 2.4 percent for the placebo group. The infusion of avidin was well- tolerated with no allergic reactions observed. Rando m i z e d, parallel Group, Multicenter, Multinational Stu d y Evaluati ng Safety of D U -176b Compared With Warfarin in Subjects With Non-Valvular Atrial ...
... a serious condition that can lead to renal failure if not controlled. The primary objective of the multi-center, open-label, randomized, parallel group comparative study was to compare the adequacy of control of PUA concentration and the safety profile in three treatment arms. Among the three ...
... in membranes, cells or tissues. NeuroSolutions' current clients include many established pharmaceutical and biotechnology companies. In parallel to running its service business, the Company is also exploiting its in-house technologies and expertise for its own internal R&D and has a mature ...
... methods (PCI or CABG). If either the cardiologist or surgeon felt that PCI or CABG was the preferred option, then patients were placed in one of two parallel registries for PCI or CABG. The safety and effectiveness of the TAXUS Express2 Stent System has not been established in patients with left main, ...
... Company enrolled and treated approximately 240 patients at a single center in the United States. The randomized, placebo-controlled, double-blind, parallel group study was designed to evaluate the efficacy and safety of multiple doses of ibuprofen 600mg ER in dental pain following molar extraction. It is ...
... SR compared to naltrexone IR. -- Preliminary evidence for improved tolerability with naltrexone SR came from a trial utilizing a multiple dose, parallel design in 60 healthy volunteers randomized to either naltrexone SR 37.5mg / bupropion SR 270mg or naltrexone IR 36mg / bupropion SR 270mg. Patients ...
... to regulatory authorities worldwide this important information, which is part of a very robust analysis of all our double-blind, placebo-controlled, parallel group trials with a duration of at least 4 weeks. Our analysis, which includes data from the four-year UPLIFT trial, supports the safety profile of ...
... subjects treated with the diclofenac patch used fewer doses of rescue medication (acetaminophen) as well. The study was a randomized, double-blind, parallel group, placebo-controlled study, in which half of the subjects received the topical diclofenac patch and the other half received a placebo ...
... the Steering Committee for IBIS-2. IBIS-2 was a 52 week, 300 participant, international, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of darapladib in subjects with angiographically documented coronary heart disease. The main objectives of the study were to determine the ...
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
... double-blind, double-dummy, randomized, positive and placebo controlled parallel study of the effects of R788 on QT/QTc intervals in healthy subjects ... 208 healthy volunteers were divided into four dosage groups and given in a parallel design either placebo, a standard dose of 100mg bid of R788, a super dose ...Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism
... placebo in a multi- center, randomized, double blind, placebo controlled parallel dose study of RA patients who have failed to respond to methotrexate. ... placebo in a multi-center, randomized, double blind, placebo controlled, parallel dose study of R788 in patients who have failed at least one marketed ...... colleagues conducted a 24-week, double-blind, randomized, dose-ranging, parallel design trial of MTC monotherapy in 321 people with Alzheimer's at 17 ... in mild Alzheimer's disease: A randomized, controlled, double-blind, parallel Group, multi-centre, multi-country clinical trial." (Funder: Danone ...
AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
... Stephen I., et al. A 12-Month Double-Blind, Double-Dummy, Randomized, parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT(R) pMDI 2 x ... Donald P., et al. A 6-Month Double-Blind, Double-Dummy, Randomized, parallel Group, Multicenter Efficacy & Safety Study of SYMBICORT(R) pMDI 2 x ...Project Zero Delay Accelerates Drug's Path to Clinical Trial
... delays while fully meeting regulatory requirements for scientific and human safety review." The key to Zero Delay was performing most tasks in parallel instead of sequentially, said lead author Razelle Kurzrock, M.D., professor and chair of M. D. Anderson's Department of Investigational Therapeutics. ...... --- --- --- Trial Design TASKi3 was a 3 month, multi-center, randomized, double blind, placebo controlled, parallel dose clinical trial involving 219 RA patients in the U.S. who had failed to respond to at least one biologic treatment (such as TNF inhibitors). The ...
... no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. (1) "Randomized, parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation," ...
Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
... -4 -20 -16 Study Design TASKi2 was a 6 month, multi-center, randomized, double blind, placebo controlled, parallel dose clinical trial involving 457 RA patients in the U.S., Latin America and Europe who had failed to respond to methotrexate alone. The patients ...Alfacell Provides Shareholder Update
... a series of animal studies on immune deficient mice to see what effect Onconase would have on human tumors grafted onto these mice. Tumorgrafts parallel sensitivity and resistance in the clinic. The results showed Onconase has a documented synergistic effect in Cisplatin sensitive and resistant NSCLC. ...Neurocrine Biosciences Presents Elagolix Data
... in which elagolix was evaluated over six weeks (42 days) in 60 healthy premenopausal women. The study was a double-blind, placebo-controlled study in parallel groups in which 88% of the participants completed the treatment period. The purpose of this study was to evaluate the safety, tolerability, ...New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
... during the 69th Annual Scientific Sessions of the American Diabetes Association (ADA). The study was a multicenter, randomized, open-label, parallel group study in insulin naive patients. Lantus(R) was started for a 14-week run-in period, after which time patients not at goal (A1C<7%) at week ...... PLX4032 works in a highly innovative way by selectively inhibiting the cancer-causing BRAF mutation, and is being developed in parallel with a companion diagnostic to identify mutation-positive patients. These data represent a significant development in the treatment of melanoma for ...
... in an extended release formulation for chronic pain. Study Design This Phase 3, double-blind, randomized, active- and placebo-controlled, parallel group, multi-center trial of 901 patients with moderate-to-severe pain following bunionectomy studied the safety and efficacy of tapentadol IR for ...
... metastatic and recurring forms of cancer. Under the alliance, GSK will develop novel antibody therapies against selected OBT targets. In parallel OBT will develop one of its own monoclonal antibodies through to clinical proof of concept, at which point GSK will have an exclusive option to ...
... for very high triglycerides and phase 2 protocols for statin combination therapy are currently being finalized with input from experts and the FDA in parallel with partnering discussions. About DCCR DCCR, diazoxide choline controlled release, is an ATP-dependent potassium channel agonist with ...
... results from the HORIZONS AMI trial showed ischemia-driven TLR was reduced by 41 percent with DES compared to BMS (4.5% vs. 7.5%, p=0.002), with parallel reduction in ischemia-driven target vessel revascularization (TVR) among patients treated with DES (5.8% vs. 8.7%, p=0.006). Angiographic follow-up ...
Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
... School of Medicine's Center for Vaccine Development notes, "Development of Sanaria's vaccine candidate is based in part on the findings from parallel studies conducted in the early 1970s by teams at the Center for Vaccine Development and the Naval Medical Research Center -- findings that were never ...... Design The efficacy and safety of TRILIPIX in combination with rosuvastatin calcium was evaluated in a multicenter, randomized, double-blind, parallel group, 12-week, Phase III study of 760 patients with mixed dyslipidemia. Patients included in the study had multiple lipid problems, with an LDL ...
... President and CEO commented, "We are delighted to have completed patient enrolment in this phase 3 cardiac surgery trial, which we are running in parallel with the second phase 3 trial in colorectal surgery. Previous meetings with FDA have indicated that no other clinical trials are necessary for NDA ...
... Phase I clinical trials in the U.S. and continues to work closely with KLS in order to coordinate their regulatory efforts and efficiently conduct parallel clinical trials for TG-C in both the U.S. and Korea. The Phase IIa clinical trial is designed as a randomized, multi-center study in order to ...
Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
... endpoint of the workhorse study is target lesion failure (TLF) at 12 months, with clinical follow-up scheduled out to five years. Two additional parallel studies will evaluate the PROMUS Element Stent in small vessels and long lesions. The small vessel study will examine lesions from 2.25 to 2.50 mm ...Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
... and Grifols, a Spanish holding company specialising in the pharmaceutical hospital industry. Other new investors were not disclosed. In parallel with this equity fund raising Cardio3 BioSciences has raised a further EUR6.5 million in cash advances from the Walloon Region General Directorate ...... Amicus and its partner Shire HGT plan additional discussions with the EMEA in the first half of 2009 to finalize the design of this study. In parallel with the Phase 3 regulatory discussions, 23 of the original 26 patients from the Phase 2 studies continue to be treated in a voluntary extension ...
Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
... system of the lungs, which will follow the successful completion of its Phase I trials. The company intends to carry out European Phase II trials in parallel with similar trials in the USA and Canada. The resulting increased visibility in Europe will further raise the profile of the company. About ...Sosei Confirms the Safety of SD118 in Two Phase I Trials
... in membranes, cells or tissues. NeuroSolutions' current clients include many established pharmaceutical and biotechnology companies. In parallel to running its service business, the Company is also exploiting its in-house technologies and expertise for its own internal R&D and has a mature ...... 2.4 percent for the placebo group. The infusion of avidin was well- tolerated with no allergic reactions observed. Rando m i z e d, parallel Group, Multicenter, Multinational Stu d y Evaluati ng Safety of D U -176b Compared With Warfarin in Subjects With Non-Valvular Atrial ...
... a serious condition that can lead to renal failure if not controlled. The primary objective of the multi-center, open-label, randomized, parallel group comparative study was to compare the adequacy of control of PUA concentration and the safety profile in three treatment arms. Among the three ...
Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease
... trial in adults. In addition, Enobia has regulatory approval to enroll several additional severely affected infants who meet study criteria in a parallel study. There is no approved treatment for the disease. To date Winnipeg is the only approved study site for the infantile protocol. The ...... in membranes, cells or tissues. NeuroSolutions' current clients include many established pharmaceutical and biotechnology companies. In parallel to running its service business, the Company is also exploiting its in-house technologies and expertise for its own internal R&D and has a mature ...
NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study
... Additional note on study design: The 111 study was a 12-week pharmacodynamic ABPM trial (with 9 weeks of active treatment), with a double-blind, parallel group design, in which 118 OA patients with controlled hypertension were enrolled at 30 clinical sites in the United States. Eligible patients were ...... methods (PCI or CABG). If either the cardiologist or surgeon felt that PCI or CABG was the preferred option, then patients were placed in one of two parallel registries for PCI or CABG. The safety and effectiveness of the TAXUS Express2 Stent System has not been established in patients with left main, ...
... Company enrolled and treated approximately 240 patients at a single center in the United States. The randomized, placebo-controlled, double-blind, parallel group study was designed to evaluate the efficacy and safety of multiple doses of ibuprofen 600mg ER in dental pain following molar extraction. It is ...
Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
... study is target lesion failure (TLF) at 12 months, and its secondary endpoint is in-segment percent diameter stenosis at nine months. A second parallel study named the TAXUS PERSEUS Small Vessel study will compare the TAXUS Element Stent to a historic control (TAXUS V de novo bare-metal Express(R) ...... SR compared to naltrexone IR. -- Preliminary evidence for improved tolerability with naltrexone SR came from a trial utilizing a multiple dose, parallel design in 60 healthy volunteers randomized to either naltrexone SR 37.5mg / bupropion SR 270mg or naltrexone IR 36mg / bupropion SR 270mg. Patients ...
... to regulatory authorities worldwide this important information, which is part of a very robust analysis of all our double-blind, placebo-controlled, parallel group trials with a duration of at least 4 weeks. Our analysis, which includes data from the four-year UPLIFT trial, supports the safety profile of ...
Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease
... a potential treatment for the disease. The Phase III trial is a prospective, 18-month, randomized, double-blind, placebo-controlled, two dose-arm, parallel study in 360 subjects of both genders, ages 50 to 89 years old, with dementia of mild-to-moderate severity. The study will determine whether ...Queen's University Chooses Xceed's Ziplex(R) System for Translational Research
... translational research. Xceed designed the Ziplex System with turnkey functionality and significant advances in automation, array format, fluidics, parallel sample processing, and analytics to minimize complexity, user interaction, and variability between users and sites. About Xceed Molecular ( ...... subjects treated with the diclofenac patch used fewer doses of rescue medication (acetaminophen) as well. The study was a randomized, double-blind, parallel group, placebo-controlled study, in which half of the subjects received the topical diclofenac patch and the other half received a placebo ...
... the Steering Committee for IBIS-2. IBIS-2 was a 52 week, 300 participant, international, multicenter, randomized, double-blind, placebo-controlled, parallel group trial of darapladib in subjects with angiographically documented coronary heart disease. The main objectives of the study were to determine the ...
Other ContentsautotrophsautotrophsautosomesautotrophicbacillibacillithuringiensisthuringiensisbacillusbacillusbacillusOther TagsPhasePhasePhasePhasePhasePhasePhospholipid
(Date:12/16/2009)... exposure to pesticides in rivers and basins may ... populations. In addition to the widespread deterioration of ... commonly used pesticides may further inhibit the recovery ... efforts are currently underway to restore Pacific salmon ... says David Baldwin of the National Oceanic and ...
(Date:12/16/2009)... Tom Bowman, an expert in communicating scientific issues ... has developed a series of graphics that translate key ... (IPCC) report for public audiences. These new graphics provide ... to make informed decisions about climate change risks and ... means to clearly and accurately communicate findings in the ...
(Date:12/16/2009)... a global provider of business process outsourcing (BPO) services, ... Awards Top 100 IT project of 2009 for its ... for iQor. ,, "We are honored to be recognized ... president and CEO of iQor. "TeQ21 is completely transforming ... faster, smarter and with the added security biometrics provides. ...
Breaking Biology News(10 mins):Even at sublethal levels, pesticides may slow the recovery of wild salmon populations 2Bowman creates graphic translation of climate change data 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Cornell Researchers Identify a Weak Link in Cancer Cell Armor 61240 1Cornell Researchers Identify a Weak Link in Cancer Cell Armor 61240 2Medical Tourism Hits Oprah com 61238 1Medical Tourism Hits Oprah com 61238 2 Integrative Neurologist Breaks Ground in Alzheimer 26apos 3Bs Prevention 61235 1 Integrative Neurologist Breaks Ground in Alzheimer 26apos 3Bs Prevention 61235 2(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary Center ... the National Heart, Lung, and Blood Institute to ... with lung disease. , Darrell Kotton, MD, ... Mostoslavsky, MD, PhD, assistant professor of medicine, are ... Together Kotton and Mostoslavsky lead a multicenter investigative ...
(Date:12/16/2009)... dying hospitalized children ask their physicians to pray with ... such personal requests? While increasing numbers of physicians say ... cope with serious illness, a new study reports that ... raise the issue of prayer, not the doctors themselves. ... Journal , Brandeis and Rice University sociologists report for ...
(Date:12/16/2009)... Customer Satisfaction, New Partners and Global Market Expansion , ... ... a provider of Feedback Analytics to Web sites and companies, today ... of 25,000 new customers. Since its launch on July 2008, ... than 60 languages, and amassed more than 30,000 customers in 191 ...
(Date:12/16/2009)... screenings conducted through national AAD program ... person dies from melanoma, the deadliest form of ... often successfully treated, if caught early. That,s why ... skin cancer screenings in their communities through the ... Screening Program. The program recently reached a milestone ...
(Date:12/16/2009)... SEATTLE, Dec. 16 For ages, people from ... its therapeutic properties. Its soothing waters have a reputation ... cites its involvement with miracles. Now, with the introduction ... ), bathers can enjoy the legendary benefits of Dead ... bath salt lines contain all-natural Dead Sea salt and ...
Breaking Medicine News(10 mins):Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Prayer on the hospital floor 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5Health News:Dermatologists Reach Skin Cancer Screening Milestone 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 3Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3[0] Boston University School of Medicine's pulmonary center receives $1.4 million grant[0] Prayer on the hospital floor[0] Kampyle Experiences Record Growth in 2009 with 25,000 New Customers [0] Dermatologists Reach Skin Cancer Screening Milestone[0] SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea
PhagemidPhagocytesPharynxPhasePhenotypicPhloemPhosphodiesterPhosphorylationPhospholipidPhotoautotrophPhotolysisPhotobiologyPhotonPhotosynthesis
Other Tagsbath 2mine 2supposed 2supposed 3supposed 4supposed 5supposed 6supposed 7supposed 8supposed 9scientist 2scientist 3scientist 4scientist 5scientist 6scientist 7scientist 8scientist 9scientist 10capability 2capability 3capability 4surgical 2surgical 3surgical 4surgical 5surgical 6precise 2precise 3precise 4precise 5precise 6precise 7precise 8precise 9precise 10laser 2laser 3laser 4| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |